Compiled by Magnolia Ark Team | For patients with advanced lung cancer who cannot undergo surgery, in addition to controlling the disease as much as possible, they also need to treat as actively as possible while avoiding side effects and disease progression to obtain a good prognosis. In recent years, the emergence of immune combined with radical radiotherapy and dual immunotherapy has brought new hope to patients with unresectable advanced lung cancer and significantly prolonged the patient's survival.
▲Photo source: cytocare
11111hm2
It is understood that is currently using immunotherapy after synchronous chemotherapy to treat has become the standard treatment method for locally advanced non-small cell lung cancer (stage III/recurrent non-small cell lung cancer) . However, some patients are still unable to complete radical radiation therapy, and immunotherapy cannot play its role.
Recently, researchers from Japan announced the results of the first phase II study of the combination of immunotherapy and radical radiation therapy for unresectable locally advanced non-small cell lung cancer.
▲Photo source: Reference source [1]
The study included 35 adult patients with unresectable locally advanced non-small cell lung cancer with ECOG performance status (PS) 0-1 and PD-L1≥1%. These patients were treated with radical radiotherapy (60Gy) + Durvalumab (Imfinzi) combined with maintenance treatment with duvalumab. The results of the
study show that the 1-year progression-free survival rate after was 72.1%, with a response rate of up to 90.9%, and the complete response rate (OR) and partial response (CR) rates were 36.4% and 54.5% , respectively.
study confirmed that the use of immunotherapy synchronous radical radiotherapy is of great significance for locally advanced non-small cell lung cancer, and can further improve the survival rate of patients with advanced non-small cell lung cancer.
1dual immunotherapy 18 months overall survival rate is as high as 85.7%
Previous studies have confirmed that the emergence of dual immunotherapy has further prolonged the survival of lung cancer patients and effectively improved the prognosis of lung cancer patients. A study released recently compared the effects of monotherapy with PD-1 inhibitor nivolumab (Nivolumab, OPDIVO, "O" drug) or dual immunotherapy with nivolumab and CTLA-4 inhibitor ipilimumab (Iipilimumab, Yervoy, "Y" drug) after synchronous chemoradiation and chemotherapy for unresectable stage III non-small cell lung cancer.
▲Photo source: Reference source [2]
A total of 105 patients with stage IIIA/IIIB non-small cell lung cancer were included in the study. The results showed that both immunoselectrotherapy and dual immunotherapy improved the progression-free survival and overall survival of lung cancer patients, among which the prognosis of dual immunotherapy was relatively higher. The specific data are that the 18-month progression-free survival rate of with nivolumab monotherapy was 64.0%, the 18-month progression-free survival rate of 67.7% with dual immunotherapy; the 18-month overall survival rate of nivolumab monotherapy was 82.8%, and the 2-month dual immunotherapy was 85.7% . However, in the incidence of adverse events in , dual immunotherapy is relatively high.
Currently, in addition to immunotherapy, there are many clinical treatment methods for patients with unresectable non-small cell lung cancer, such as targeted therapy, proton heavy ion therapy, etc. . However, each therapy has its indication requirements, and it is necessary to comprehensively evaluate the patient's condition and physical condition to judge the best treatment method.
Therefore, for patients who unfortunately suffer from non-small cell lung cancer, the most important thing for is to find authoritative hospitals and doctors to see the doctor as soon as possible, choose the most appropriate treatment plan, and improve the prognosis effect . Professor Kubota Kyuki, director of the Cancer Center of the Affiliated Hospital of Japan Medical University, is an expert in lung cancer drug treatment. In the field of lung cancer drug treatment, Professor Kubota Kyuki actively introduces new drugs, participates in the international clinical trials of anti-cancer drugs and immune drugs, and constantly seeks new treatment methods.
As a signing cooperation expert on Houpu Ark, Professor Xin Kubo has received patients from China many times and provides diagnosis and treatment hope for lung cancer patients in China. If you or your friends are also suffering from the threat or trouble of lung cancer, and you hope to make an appointment quickly for Professor Kubota to get more effective medical advice, you can contact Magnolia Ark.
Reference source:
[1]Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC: DOLPHIN Study | IASLC
https://www.iaslc.org/iaslc-news/press-release/phase-ii-study-durvalumab-plus-concurrent-radiotherapy-unresectable
[2]Consolidation Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiation for Patients with Unresectable Stage III NSCLC | IASLC
https://www.iaslc.org/iaslc-news/press-release/consolidation-nivolumab-and-ipilimumab-or-nivolumab-alone-following
